Nan Chen, MD

Nan Chen, MD, discusses ADC-associated toxicity management in breast cancer, as well as the evolving role of oral SERDs in ER-positive disease.

Nan Chen, MD, discusses the investigation of CDK4/6 inhibitors in early-stage breast cancer.